QR-koodi

PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability

Protein kinase C α (PKCα) regulates diverse biological functions of cancer cells and is a promising therapeutic target. However, clinical trials of PKC-targeted therapies have not yielded satisfactory results. Recent studies have also indicated a tumor-suppressive role of PKCs via unclear molecular...

Täydet tiedot

Tallennettuna:
Päätekijät: Jiaojiao Yu, Yujin Xiang, Yuzhen Gao, Shan Chang, Ren Kong, Xiaoxi Lv, Jinmei Yu, Yunjie Jin, Chenxi Li, Yiran Ma, Zhenhe Wang, Jichao Zhou, Hongyu Yuan, Shuang Shang, Fang Hua, Xiaowei Zhang, Bing Cui, Pingping Li
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2024-10-01
Sarja:Acta Pharmaceutica Sinica B
Aiheet:
Protein kinase C
PD-L1
β-TRCP
Degradation
Immune evasion
Immunotherapy
Linkit:http://www.sciencedirect.com/science/article/pii/S2211383524003198
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia